Sari Pesonen

Company: Valo Therapeutics

Job title: Co-Founder & Chief Scientific Officer

Seminars:

First-in-Human Clinical Trial with Intratumoral PeptiCRAd-1 in Combination with Pembrolizumab: Assessment of Safety & Immunological MoA 4:00 pm

• PeptiCRAd technology combines OV and peptide vaccine providing a flexible therapeutic vaccine platform focused on generating cytotoxic T cell responses • First-in-human clinical trial in combination with PeptiCRAd-1 and pembrolizumab starting early 2022 • Extensive immune monitoring planned for the assessment of MoA and biomarker identificationRead more

day: Track A - Day 1 pm